Novo Holdings A/S

CIK: 0001388325

Transaction Breakdown

Open Market Buys (P)2 (40.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)3 (60.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

COAG

Hemab Therapeutics Holdings, Inc.

10% Owner

AVLN

Avalyn Pharma Inc.

10% Owner

MPLT

MapLight Therapeutics, Inc.

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (5 total)

COAG
Hemab Therapeutics Holdings, Inc.
May 4, 2026
Conversion(C)
Direct
4.2M shares-
AVLN
Avalyn Pharma Inc.
May 1, 2026
Conversion(C)
Direct
3.3M shares-
AVLN
Avalyn Pharma Inc.
May 1, 2026
Purchase(P)
Direct
555.6K shares at avg. $18.00$10.0M
MPLT
MapLight Therapeutics, Inc.
Oct 28, 2025
Conversion(C)
Direct
2.7M shares-
MPLT
MapLight Therapeutics, Inc.
Oct 28, 2025
Purchase(P)
Direct
952.9K shares at avg. $17.00$16.2M

		Type	Shares	Price		Ownership
May 4, 2026	COAG Hemab Therapeutics Holdings, Inc.	Conversion(C)	4,180,550	-	$0	Direct
May 1, 2026	AVLN Avalyn Pharma Inc.	Conversion(C)	3,327,734	-	$0	Direct
May 1, 2026	AVLN Avalyn Pharma Inc.	Purchase(P)	555,555	$18.00	$9,999,990	Direct
Oct 28, 2025	MPLT MapLight Therapeutics, Inc.	Conversion(C)	2,733,681	-	-	Direct
Oct 28, 2025	MPLT MapLight Therapeutics, Inc.	Purchase(P)	952,941	$17.00	$16,199,997	Direct

1-5 of 5 transactions

About Novo Holdings A/S

Novo Holdings A/S (SEC CIK 0001388325) files insider reports with the SEC as 10% Owner of Hemab Therapeutics Holdings, Inc. (COAG), 10% Owner of Avalyn Pharma Inc. (AVLN) and 10% Owner of MapLight Therapeutics, Inc. (MPLT).

Signal8 holds 5 ownership filings by Novo Holdings A/S (2 Form 3, 3 Form 4), filed between Oct 27, 2025 and May 6, 2026. Those filings report 5 transactions, from Oct 28, 2025 to May 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Novo Holdings A/S's filings is in HELLERUP.

Recent filings by Novo Holdings A/S

May 4, 2026: Conversion of COAG shares (Form 4, code C).
May 1, 2026: Conversion of AVLN shares (Form 4, code C).
May 1, 2026: Open-market purchase of AVLN shares (Form 4, code P).
Oct 28, 2025: Conversion of MPLT shares (Form 4, code C).
Oct 28, 2025: Open-market purchase of MPLT shares (Form 4, code P).

Other insiders filing for Hemab Therapeutics Holdings, Inc. (COAG)

Walbert Keli, Director
RA CAPITAL MANAGEMENT, L.P., 10% Owner
AI DEN-MAB LLC, 10% Owner
MARAGANORE JOHN, Director
Madigan Catherine, Chief Medical Officer
Behrndt-Eriksen Mads Nikolaj

How to read Form 4 transaction codes